Open in interactive viewer → charts, metric popovers & call review

KP Tissue's Growth Engine Is Running—Just Not Into a New TAD Plant Yet

Q3 revenue and EBITDA rose, but KP deferred its next flagship facility beyond 2028 and flagged a 2027 cost wall that could force consumer price increases.
KPT.TO · Earnings Call · 2026-11-11

A good quarter with a strategic asterisk

KP Tissue's third quarter was, on the surface, exactly what a defensive consumer-staples holder wants: “Our continued strong momentum in the third quarter has led us to deliver more than 3 consecutive years of profitable growth.” — Dino Bianco, Chief Executive Officer · 2026-11-11 Revenue rose 5.1% to $589.7 million, adjusted EBITDA rose 9.1% to $93.5 million, and net income nearly doubled to $27.7 million from $14.6 million. Canada grew 3.2%, the U.S. grew 7.3%, and the consumer segment's margin improved to 17.9%. The balance sheet also improved: cash of $176.4 million, total debt down $18.4 million sequentially, and leverage at 2.7x versus 2.9x in Q2.

But the strategically important sentence was about the future, not the quarter. KP said its next TAD facility—the premium tissue capacity meant to anchor U.S. growth—will not start operations in 2028, and a final investment decision is deferred until there is more certainty in the trade environment. That is a capital-allocation pivot dressed up as a timing update. The project is not dead: engineering work, local incentives and lender conversations continue. But the company is no longer pretending a decision is imminent.

We're also making progress on our new TAD facility. However, a final decision will be deferred until there is greater certainty in the economic and trade environment. Accordingly, we anticipate that the new TAD facility will be delayed and will not commence operations in 2028.

Dino Bianco, Chief Executive Officer · 2026-11-11


This is the third consecutive call in which the TAD timeline has moved. In February, management said it assumed the remaining work would be done “in time for us to make an announcement in the first half.” — Dino Bianco, Chief Executive Officer · 2026-02-18 By August, the hope was “before we got out of this year that we would have -- we provide clarity.” — Dino Bianco, Chief Executive Officer · 2026-08-13 Now the answer is effectively: not yet, and not in 2028. That is the tension in the report. The operating business is performing; the next leg of the growth story is on hold.

From pulp tailwind to a 2027 cost-basket problem

The Q3 margin story was helped by pulp. Average NBSK prices fell 6.2% year over year on overcapacity, while BEK rose more than 30%. Industry analysts expect NBSK prices to trend upward from here, and management is already planning for it. Dino Bianco was explicit: “we see pulp, particularly, NBSK moving up in 2027, which will then create a cost basket that's going to require action to maintain our margin.” — Dino Bianco, Chief Executive Officer · 2026-11-11

That cost basket is broader than pulp. Transportation costs escalated through 2026, packaging and petroleum-based inputs are elevated, and the company expects those pressures to stay high. The consolidated adjusted EBITDA margin improved year over year to 15.9% from 15.3%, but it slipped sequentially from 16.4% in Q2. Management guided Q4 adjusted EBITDA slightly below Q3 while still above the prior-year quarter—and then added the line that matters: “fourth quarter is always a wildcard.” — Dino Bianco, Chief Executive Officer · 2026-11-11

The offset has to come from productivity initiatives and price. KP last took consumer pricing in 2024; it priced its Away-From-Home business on September 1. On the consumer side, the modeling is done but no announcement has been made. “We have not made any official announcements. But if -- that could be pending very shortly.” — Dino Bianco, Chief Executive Officer · 2026-11-11 That is the real swing factor for 2027. If input costs rise as feared, KP needs to pass them through without derailing the Canadian share recovery it is trying to fund.

Canada's share recovery is working—but not yet winning

The Canadian consumer business remains the most important brand franchise. The company says it saw share pressure in bathroom tissue and paper towels against a softer Canadian market, while facial tissue held up. Its response is the trademark recovery plan: brand investment, targeted pricing, promotional activity, innovation and retail execution. Early results are described as encouraging—Scotties and Bonterra are performing, and SpongeTowels is starting to respond. But this is a repeat of the August call, when management was already talking about correcting price gaps and securing additional promotional activity after share erosion began in the spring.

That makes the Canadian recovery a show-me story. The company is rebuilding share with a combination of marketing and price, not a single new product cycle. The risk is that the cost inflation now hitting the system forces KP to choose between margin and volume. The opportunity is that its Made-in-Canada positioning and brand portfolio still give it a defensible right to compete.

Away From Home: growth without margin leverage

The Away From Home segment—Kruger PRO—grew revenue 4.4% to $96.9 million, but adjusted EBITDA fell to $8.9 million from $10.4 million a year ago, and the margin was 9.2%. The culprit was higher logistics costs; the company has already pushed through a price increase to offset fuel and transportation inflation. Management argues there is still room to expand margins through mix, wipes and wipers, and network costs, and that AFH is now an investable business rather than a fixer-upper. “I do believe there's margin upside there. I'm not going to declare a number.” — Dino Bianco, Chief Executive Officer · 2026-11-11

But the prior ambition was clearer. In February, Bianco said AFH should be in the “low double digits” — Dino Bianco, Chief Executive Officer · 2026-02-18 over the long term. A 9.2% margin is high-single-digit, not yet low-double-digit. The segment is growing and is no longer a drag, but it has not yet delivered the margin step-up that would make it a genuine second engine.

What to watch from here

The near-term setup is unusual for a small-cap tissue maker. KP is generating enough cash to cut debt and lower leverage, and it is deliberately slowing its largest growth project. Management lowered 2026 capex to $80 million-$100 million and guided 2027 capex to $60 million-$80 million, excluding TAD. That is a free-cash-flow-friendly posture if the trade fog persists—but it also means the U.S. premium-capacity story is deferred, and the company will lean on existing assets in Sherbrooke and Memphis to grow. Dino says the project has not stopped and “we don't have to restart,” — Sean Steuart, Analyst · 2026-11-11 which is reassuring operationally but does not remove the strategic delay.

The market's broader tape has been crowded with tariff and trade-policy uncertainty; for KP, that macro theme has become a gating item for capital spending, not just a cost line. The company's own keyword profile has flipped accordingly: TAD facility and trade environment now sit at the top, while input cost and transportation costs remain persistent. The quarter was good enough to keep the earnings story intact. The next chapter depends on two things management cannot fully control: whether trade clarity arrives, and whether consumers absorb another round of tissue pricing.